Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY antimicrobial surveillance program (1998)

This publication has 15 references indexed in Scilit:

• In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
  Antimicrobial Agents and Chemotherapy, 1997
• A multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens in the United States, 1992–1994
  Diagnostic Microbiology and Infectious Disease, 1996
• Colonization and infection withMoraxella catarrhalis in childhood
  European Journal of Clinical Microbiology & Infectious Diseases, 1996
• Moraxella catarrhalis: Pathogenic Significance in Respiratory Tract Infections Treated by Community Practitioners
  Clinical Infectious Diseases, 1996
• In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993
  Antimicrobial Agents and Chemotherapy, 1994
• Antibiotic susceptibilities and drug resistance in Moraxella (Branhamella) catarrhalis
  The American Journal of Medicine, 1990
• Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis
  Antimicrobial Agents and Chemotherapy, 1989
• BETA-LACTAMASE-PRODUCING BRANHAMELLA IN BEIJING, CHINA
  The Pediatric Infectious Disease Journal, 1988
• Sensitivity of Branhamella catarrhalis to Oral Antibiotics
  Drugs, 1986
• CLINICAL AND MICROBIOLOGICAL FEATURES OF BRANHAMELLA CATARRHALIS BRONCHOPULMONARY INFECTIONS
  The Lancet, 1984